{"entity":{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","aka":[],"tldr":"A phase 1/2 trial of Olaparib and Bevacizumab in ovarian cancer, small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT02734004 by AstraZeneca, with 264 participants enrolled, started 2016-03-17 and due to reach its primary completion in 2021-09-17. Interventions recorded: Olaparib, MEDI4736 and Bevacizumab. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02734004","url":"https://clinicaltrials.gov/study/NCT02734004"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","sclc","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["olaparib","bevacizumab"],"companies":["astrazeneca","iqvia"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02734004","phase":"1/2","setting":"A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors","sponsor":"AstraZeneca","enrolled":264,"outcomes":[]},"route":"/trials/nct02734004/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"iqvia","kind":"company","name":"IQVIA","route":"/companies/iqvia/"}]}}